EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis

Jason E Cummings, Christopher S Lunde, M R K Alley, Richard A Slayden iD

PLOS Neglected Tropical Diseases · 2023

DOI: 10.1371/journal.pntd.0011795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2023. Verfasst von Jason E Cummings und 3 weiteren Autor:innen. Beteiligte Einrichtung: Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America. Hauptthemen laut MEDLINE: Burkholderia pseudomallei, Melioidosis, Amino Acyl-tRNA Synthetases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Colorado State University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Burkholderia pseudomallei is the causative agent of melioidosis, which is increasingly being reported worldwide. Mortality rates as high as 40% have been reported based on clinical patient outcomes in the endemic areas of Australia and Thailand. Novel therapies are needed to reduce treatment duration and adverse effects and improve treatment outcomes. Epetraborole, a novel antibiotic, targets leucyl-tRNA synthetase (LeuRS), an essential enzyme that catalyzes the attachment of leucine to transfer RNA. Epetraborole was evaluated for in vitro activity and efficacy in a murine model to assess clinical relevance against Burkholderia pseudomallei infections for possible treatment of melioidosis. Epetraborole was tested against 13 clinically derived and three reference B . pseudomallei strains that have a broad spectrum of susceptibilities to the standard-of-care (SoC) drugs for melioidosis, which showed that epetraborole exhibited minimal inhibitory concentrations of 0.25–4 μg/mL. Ex vivo studies using THP-1 macrophages confirmed the potency of epetraborole and demonstrated synergy between epetraborole and ceftazidime. In the acute pulmonary murine infection model of melioidosis, epetraborole demonstrated equivalent efficacy when delivered orally or subcutaneously, which compared well with the standard-of-care drug ceftazidime. In addition, adding epetraborole to ceftazidime significantly improved antimicrobial activity in this animal model. This work warrants further exploration of epetraborole as a candidate for treating melioidosis and substantiates LeuRS as a clinically relevant drug target in B . pseudomallei .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Burkholderia pseudomalleiMelioidosisAmino Acyl-tRNA SynthetasesAnimalsMiceHumansCeftazidimeAnti-Bacterial Agents

Substanzen

CeftazidimeAnti-Bacterial AgentsAmino Acyl-tRNA Synthetases

Autor:innen und Institutionen

  • Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
  • AN2 Therapeutics, Menlo Park, California, United States of America.

ORCID-Profile: Richard A Slayden

Förderung

  • Colorado State University

Zitieren

APA

Cummings, J. E., Lunde, C. S., Alley, M. R. K., & Slayden, R. A. (2023). Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0011795

Vancouver

Cummings JE, Lunde CS, Alley MRK, Slayden RA. Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis. PLOS Neglected Tropical Diseases. 2023. doi:10.1371/journal.pntd.0011795

BibTeX
@article{Cummings2023,
  author = {Cummings, Jason E and Lunde, Christopher S and Alley, M R K and Slayden, Richard A},
  title = {Epetraborole, a leucyl-tRNA synthetase inhibitor, demonstrates murine efficacy, enhancing the in vivo activity of ceftazidime against Burkholderia pseudomallei, the causative agent of melioidosis},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2023},
  doi = {10.1371/journal.pntd.0011795}
}
Kostenlos starten →